Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models
Runhong Zhou, Pui Wang, Yik-Chun Wong, et al.
EBioMedicine (2021) Vol. 75, pp. 103762-103762
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Qiaoli Peng, Runhong Zhou, Yuewen Wang, et al.
EBioMedicine (2022) Vol. 77, pp. 103904-103904
Open Access | Times Cited: 113
Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
Daniele Focosi, Fabrizio Maggi, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 2, pp. 187-187
Open Access | Times Cited: 87
Expansion of cytotoxic tissue-resident CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19 vaccination
Aloysious Ssemaganda, Huong Mai Nguyen, Faisal Nuhu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 67
An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters
Shaofeng Deng, Ying Liu, Rachel Chun-Yee Tam, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 25
Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses
Wenjiao Fu, Mengyu Guo, Xuemei Zhou, et al.
ACS Nano (2024) Vol. 18, Iss. 17, pp. 11200-11216
Closed Access | Times Cited: 9
Bioinspired Lipid Nanocarriers for RNA Delivery
Alex Golubovic, Shannon J. Tsai, Bowen Li
ACS Bio & Med Chem Au (2023) Vol. 3, Iss. 2, pp. 114-136
Open Access | Times Cited: 16
Olfactory immune response to SARS-CoV-2
Sebastian A. Wellford, E. Ashley Moseman
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 134-143
Open Access | Times Cited: 14
Olfactory immunology: the missing piece in airway and CNS defence
Sebastian A. Wellford, E. Ashley Moseman
Nature reviews. Immunology (2023) Vol. 24, Iss. 6, pp. 381-398
Closed Access | Times Cited: 13
Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
Rick Heida, Henderik W. Frijlink, Wouter L.J. Hinrichs
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 12
Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch
Benjamin Hewins, Motiur Rahman, Jesús F. Bermejo-Martín, et al.
Frontiers in Virology (2022) Vol. 2
Open Access | Times Cited: 16
Single intranasal immunization with a high dose of influenza vector protects against infection with heterologous influenza virus and SARS-CoV-2 in ferrets and hamsters
Andrej Egorov, Artem Krokhin, И. А. Ленева, et al.
Microbiology Independent Research Journal (MIR Journal) (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques
Bryce M. Warner, Mable Chan, Nikesh Tailor, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 404-404
Open Access | Times Cited: 2
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
Ramireddy Bommireddy, Shannon Stone, Noopur Bhatnagar, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 944-944
Open Access | Times Cited: 13
Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2
Wei‐Chiao Huang, Kevin Chiem, Luis Martínez‐Sobrido, et al.
Pathogens (2022) Vol. 11, Iss. 9, pp. 1035-1035
Open Access | Times Cited: 13
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults
Ruiqi Zhang, Kwok‐Hung Chan, Pui Wang, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 723-723
Open Access | Times Cited: 7
The in vitro and in vivo antibacterial activities of uniflorous honey from a medicinal plant, Scrophularia ningpoensis Hemsl., and characterization of its chemical profile with UPLC-MS/MS
Tianxing Lin, Lei Huang, Ningna Cheng, et al.
Journal of Ethnopharmacology (2022) Vol. 296, pp. 115499-115499
Open Access | Times Cited: 12
Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
Katherine S. Lee, Nathaniel A. Rader, Olivia A. Miller-Stump, et al.
Vaccine (2023) Vol. 41, Iss. 34, pp. 5003-5017
Open Access | Times Cited: 6
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity
Ileana García-Silva, Dania O. Govea‐Alonso, Sergio Rosales‐Mendoza
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 2, pp. 207-222
Closed Access | Times Cited: 5
Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice
Nathaniel A. Rader, Katherine S. Lee, Andrea N. Loes, et al.
Vaccine X (2024) Vol. 20, pp. 100543-100543
Open Access | Times Cited: 1
Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2
Khue G. Nguyen, Siena M. Mantooth, Maura R. Vrabel, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Tissue-Resident Memory T Cell: Ontogenetic Cellular Mechanism and Clinical Translation
Haoran Xu, Runhong Zhou, Zhiwei Chen
Clinical & Experimental Immunology (2023) Vol. 214, Iss. 3, pp. 249-259
Open Access | Times Cited: 4
A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern
Dandan Wu, Junxiao Cong, Jiali Wei, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 5781-5795
Open Access | Times Cited: 3
Investigation of Possible Factors Influencing the Neutralizing Anti-SARS-CoV-2 Antibody Titer after Six Months from the Second Vaccination Dose in a Sample of Italian Nursing Home Personnel
Alberto Modenese, Stefania Paduano, Rossana Bellucci, et al.
Antibodies (2022) Vol. 11, Iss. 3, pp. 59-59
Open Access | Times Cited: 4
Heterologous Systemic Prime–Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as well as Protection in Hamsters
Paidamoyo M. Katsande, Leira Fernández‐Bastit, William T. Ferreira, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1900-1900
Open Access | Times Cited: 4
Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission
Madison Stoddard, Alexander Novokhodko, Sharanya Sarkar, et al.
COVID (2022) Vol. 2, Iss. 12, pp. 1689-1709
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top